Skip to main content

Month: February 2026

Beeline to Integrate Its Digital Quality Control Platform, BLINKQC, Into Encompass Platform, Expanding Access to Over 3,100 Mortgage Lenders

Collaboration with Stellar Innovation and Integration with ICE Mortgage Technology’s Encompass® System, Expands BLINKQC’s Presence PROVIDENCE, R.I., Feb. 03, 2026 (GLOBE NEWSWIRE) — via IBN – Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform redefining the path to homeownership, today announced it has entered into an agreement with Stellar Innovations to integrate Beeline’s proprietary BLINKQC quality control solution into the Encompass® loan origination system by ICE Mortgage Technology. The integration is expected to be live within approximately 90 days. Encompass is the most widely used loan origination system in the U.S., licensed by approximately 3,100 lenders and relied upon by banks, credit unions, and mortgage bankers—particularly mid- to large-scale institutions. Upon completion, the integration...

Continue reading

Ardelyx Receives New Patent for Tenapanor

New patent covers IBSRELA® and XPHOZAH® and expires in 2042 WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26, 2042. The patent relates to the formulation of tenapanor and covers the commercial formulations of IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The patent will be submitted to the Food and Drug Administration for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for both...

Continue reading

Orion Announces $4M Project to Install 105 EV Charging Stations For Boston Public Schools

MANITOWOC, Wis., Feb. 03, 2026 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations and maintenance services solutions, today announced an installation project of 105 EV charging stations and related infrastructure in the Boston (MA.) Public School (“BPS”) system. The contract is valued at $4 million. Orion’s Voltrek division is installing 105 DC fast charging stations and related infrastructure at the Freeport Bus Yard operated by the Boston Public Schools, one of the company’s largest customers and one of the most prominent school districts in the United States. Like a number of Orion/Voltrek installations for BPS, the new units feature an innovative above-ground mounting method with Jersey barriers. Orion/Voltrek is...

Continue reading

Osisko Development Completes US$143.8 Million “Bought Deal” Public Offering of Common Shares Including Full Exercise of Over-Allotment Option

MONTREAL, Feb. 03, 2026 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“) is pleased to announce that it has completed its previously announced prospectus offering (the “Offering“) of common shares of the Company (the “Common Shares“). The Offering was completed on a “bought deal” basis, pursuant to an underwriting agreement dated January 27, 2026, among the Company and a syndicate of underwriters comprising National Bank Capital Markets, RBC Capital Markets and Cantor, as co-lead underwriters and co-bookrunners, and BMO Capital Markets (collectively, the “Underwriters“). Pursuant to the Offering, the Company issued an aggregate of 40,607,650 Common Shares at a price of US$3.54 per Common Share for aggregate...

Continue reading

Caring Brands Secures Two New U.S. Patents Strengthening Hair Enzyme Booster Technology

Fort Pierce, FL, Feb. 03, 2026 (GLOBE NEWSWIRE) — Caring Brands Inc. (Nasdaq: CABR) today announced the issuance of two new United States patents covering proprietary methods and compositions designed to enhance enzymatic activity in hair follicles, further strengthening the Company’s intellectual property portfolio supporting its Hair Enzyme Booster product. The newly issued patents, granted by the United States Patent and Trademark Office in January 2026, relate to technologies that increase sulfotransferase enzyme activity to improve the efficacy of topical hair loss treatments. These patents expand Caring Brands’ exclusive protection around mechanisms that are central to the Hair Enzyme Booster, which is currently generating revenue through direct sales in the United States and via international licensees. The newly granted...

Continue reading

Morris State Bancshares Announces Solid Earnings in 2025 and Declares Quarterly and Special Dividend

DUBLIN, Ga., Feb. 03, 2026 (GLOBE NEWSWIRE) — Morris State Bancshares, Inc. (OTCQX: MBLU) (the “Company”), the parent of Morris Bank (the “Bank”), today reported its financial results for the quarter and year ended December 31, 2025. Year-over-year and quarter-by-quarter comparisons are included herewith. On January 28, 2026, the Company’s Board of Directors declared a quarterly cash dividend of $0.13 per common share—an increase of $0.01 per share or 8.33% over the quarterly dividend of $0.12 paid in each quarter 2025. This dividend will be payable on or about March 10, 2026, to all shareholders of record as of February 10, 2026. In addition to this quarterly dividend, the Board also approved a one-time special dividend of $0.16 per common share. This special dividend will be payable on or about March 20, 2026, to all shareholders...

Continue reading

GPGI, Inc. Declares Dividend

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) — GPGI, Inc. (NYSE: GPGI) (the “Company” or “GPGI”), a diversified multi-industry compounder comprising companies with great positions in good industries, today announced its Board of Directors has declared a quarterly cash dividend of $0.0025 per share of the Company’s Class A common stock. The dividend represents an annual distribution of approximately $2.9 million. GPGI’s capital allocation priorities remain focused on debt paydown and pursuing additional accretive acquisitions that meet the six pillars of our investment criteria. The cash dividend will be payable on February 27, 2026, to shareholders of record of Class A common stock at the close of business on February 13, 2026. About GPGI GPGI, Inc. (NYSE: GPGI) is a diversified, multi-industry compounder comprising companies with...

Continue reading

Correction: Form 8.3 – Picton Property Income Limited

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree Picton Property Income Limited(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an...

Continue reading

Allegro MicroSystems Appoints Ian Kent, Senior Vice President, Operations and Jamie Haas Vice President, Chief Technology Officer

MANCHESTER, N.H., Feb. 03, 2026 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro”) (Nasdaq: ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced that the company has promoted Ian Kent to Senior Vice President, Operations and Jamie Haas to Vice President, Chief Technology Officer. “As we sharpen our focus on executing our long-term strategy, it is critical to backfill key roles within Allegro’s senior leadership team. These promotions are the result of thoughtful consideration, including my own experience overseeing worldwide operations and technology development. This transition reflects both continuity and strength in leadership,” said Mike Doogue, Chief Executive Officer. “Ian and Jamie are the right leaders to drive our company forward. I...

Continue reading

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

        This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. Department of Veterans Affairs and is open to enrollment at 11 VA sites throughout the USTARPON SPRINGS, Fla., February 3, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that enrollment is now open for its new Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cell lung cancer (SCLC). The trial is being conducted in collaboration with the U.S. Department...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.